Extrait

-To evaluate the safety/tolerability of intravenous VX-970 administered: Part A – as multiple ascending doses in comb with gem, and with cis/gem in subjects with advanced solid tumors Part B – as multiple ascending doses in comb with cis, and with cis/etp in subjects with advanced solid tumors Part C1 - with gem in subjects with advanced NSCLC with TP53 mutation, with ATM loss of expression, and without TP53 mutation and ATM loss of expression. Part C2 - with cis in subjects with advanced TNBC Part C3 - with cis- or carboplatin in subjects with platinum-resistant advanced SCLC -To assess the ORR by RECIST 1.1 in: Part C1 - advanced NSCLC with TP53 mutation, with ATM loss of expression, and without TP53 mutation and ATM loss of expression to the comb of VX-970 and gem Part C2 - advanced TNBC who are basaloid subtype and BRCA1/BRCA2 germline wild-type to the combination of VX-970 and cis Part C3 - Pt-resistant advanced SCLC to the combination of VX 970 and cis- or carboplatin

Critère d'inclusion

• Cancer (malignant solid tumors)

Liens

• ictrp
• euctr